Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan S Maltzman

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Science Immunology|May 3, 2024
Everlasting first impressions in B cellsSoyeon Kim, Jonathan S Maltzman
Science Immunology|December 5, 2025
Sugar-coated CAR T for sweeter cell therapiesDachuan Dong, Jonathan S Maltzman
Science Immunology|July 7, 2023
TCRward personalized transplant therapiesAshima Chadha, Jonathan S Maltzman
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 9, 2020
The ONE Study: One Small Step for Patient Care, a Giant Leap for Cell TherapyCaroline Lamarche, Jonathan S Maltzman
Nature Immunology|April 22, 2008
CD3varepsilon: PeRuSing for positive selectionJonathan S Maltzman, Gary A Koretzky
The Journal of Clinical Investigation|April 17, 2003
Azathioprine: old drug, new actionsJonathan S Maltzman, Gary A Koretzky
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 30, 2012
Leukocyte: tempus fugit vel carpe diemJonathan S Maltzman, Jonathan S Bromberg
Science Immunology|May 3, 2020
Sestrins teach old T cells new tricksJonathan S Maltzman, Lauren E Higdon
Science Immunology|March 8, 2021
To debug or not to debug, a question worth askingLauren E Higdon, Jonathan S Maltzman
Seminars in Dialysis|September 30, 2005
Are inflammatory cytokines the "evil humors" that increase morbidity and cardiovascular mortality in chronic kidney disease?Jonathan S Maltzman, Jeffrey S Berns
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Science Immunology|May 3, 2024
Everlasting first impressions in B cellsSoyeon Kim, Jonathan S Maltzman
Science Immunology|December 5, 2025
Sugar-coated CAR T for sweeter cell therapiesDachuan Dong, Jonathan S Maltzman
Science Immunology|July 7, 2023
TCRward personalized transplant therapiesAshima Chadha, Jonathan S Maltzman
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 9, 2020
The ONE Study: One Small Step for Patient Care, a Giant Leap for Cell TherapyCaroline Lamarche, Jonathan S Maltzman
Nature Immunology|April 22, 2008
CD3varepsilon: PeRuSing for positive selectionJonathan S Maltzman, Gary A Koretzky
The Journal of Clinical Investigation|April 17, 2003
Azathioprine: old drug, new actionsJonathan S Maltzman, Gary A Koretzky
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 30, 2012
Leukocyte: tempus fugit vel carpe diemJonathan S Maltzman, Jonathan S Bromberg
Science Immunology|May 3, 2020
Sestrins teach old T cells new tricksJonathan S Maltzman, Lauren E Higdon
Science Immunology|March 8, 2021
To debug or not to debug, a question worth askingLauren E Higdon, Jonathan S Maltzman
Seminars in Dialysis|September 30, 2005
Are inflammatory cytokines the "evil humors" that increase morbidity and cardiovascular mortality in chronic kidney disease?Jonathan S Maltzman, Jeffrey S Berns
Pageof 9